CYTODYN INC - CYDY STOCK NEWS

CytoDyn Inc. (OTCQB: CYDY) announced an upcoming webcast for the investment community scheduled on April 11, 2023, at 1:00 PM PT / 4:00 PM ET. The update will feature key executives, including Board Chair Tanya Urbach and President Cyrus Arman, discussing the company’s progress and the potential of leronlimab, a CCR5 antagonist. Questions can be submitted prior to the event until Noon PT on April 7, 2023, and will be addressed during the presentation if appropriate. A replay will be available approximately one hour after the event until May 11, 2023.

CytoDyn Inc. (OTCQB: CYDY) will hold a webcast on December 29, 2022, at 8:00 a.m. PT to discuss the performance of its investigational drug, leronlimab, in clinical trials. The discussion will also address recent charges against former CEO Nader Pourhassan, who was terminated on January 24, 2022, and has since had no association with the company. CytoDyn is focused on developing leronlimab for various therapeutic applications, including infectious diseases, cancer, and autoimmune conditions. The webcast replay will be available until January 29, 2023.

CytoDyn Inc. (OTCQB: CYDY) will host a virtual R&D Update on December 7, 2022, at 11:00 a.m. ET. The event will feature presentations by key management and Scientific Advisory Board members discussing the clinical development of leronlimab, a CCR5 antagonist. Presenters include Cyrus Arman, M.D., who will overview the R&D strategy; Mazen Noureddin, M.D., discussing leronlimab's potential in treating NASH; Stefan Glück, M.D., focused on cancer therapy; and Jonah Sacha, Ph.D., on HIV research. The event can be accessed via the company's website.

CytoDyn (OTCQB: CYDY) announced the voluntary withdrawal of its Biologics License Application (BLA) for leronlimab, aimed at treating HIV-MDR patients. The decision stems from concerns over data quality from a clinical research organization (CRO). Despite meeting primary endpoints in trials, the company believes FDA approval is unlikely without substantial investments. CytoDyn plans to respond to a clinical hold and continue exploring leronlimab's effectiveness in other areas, including NASH and oncology, where promising results have been observed. A webcast will provide further updates on these developments.

CytoDyn Inc. (OTCQB: CYDY) announces significant changes to its Board of Directors with the appointments of Stephen Simes and Ryan Dunlap as independent directors. Simes brings over 40 years of experience in biopharmaceuticals, having successfully led various companies, while Dunlap has 25 years of finance and operations expertise. The changes aim to enhance the board’s independence and industry experience, following the resignation of Dr. Scott Kelly as a director, although he remains Chief Medical Officer. This strategic move is positioned to strengthen corporate governance and focus on CytoDyn's therapeutic developments.

CytoDyn Inc. (OTCQB: CYDY) announced an investment community webcast scheduled for September 28, 2022, at 1:00 pm PT / 4:00 pm ET. The event will feature Board Chair Tanya Urbach, President Cyrus Arman, CFO Antonio Migliarese, and CMO Scott Kelly, who will provide a quarterly update on the company's developments, particularly regarding leronlimab, a CCR5 antagonist. Questions for the webcast can be submitted until Noon PT on September 26, 2022. A replay will be available after the event until October 28, 2022.

CytoDyn Inc. (OTCQB: CYDY) announced the appointment of Dr. Cyrus Arman as President effective July 9, 2022. He brings over 15 years of experience, most recently serving as Chief Business Officer at Nimble Therapeutics. Dr. Arman is expected to transition to Chief Executive Officer and join the Board of Directors within six months. Board Chair Tanya Urbach expressed confidence in his leadership, highlighting his strategic abilities to enhance shareholder value and advance the company’s drug, leronlimab, which targets various medical conditions. Antonio Migliarese resumes his role as CFO.